“Can COVID-19 Hasten the Adoption of Virtual Trials?”

COVID-19 could be the impetus that finally drives clinical trial sponsors to look for ways to keep patients at home.

COVID-19 has changed the way people consult with their physicians and it is also likely to change the way clinical trial participants conduct study visits.

The coronavirus crisis has the potential to encourage trial sponsors to find ways to keep participants at home and accelerate the adoption of decentralized or virtual trials.

The U.S. Food and Drug Administration (FDA) has issued new guidance on conducting trials that require sponsors to prioritize patient safety and mentioned phone calls and virtual visits as ways to keep trial participants safe.

The best option for sponsors to keep patients safe is to reduce the required physical study visits and replace them with televisit and remote monitoring.

Clinical Innovation Partners founder Craig Lipset and Patients Can’t Wait president Jeff Kasher both feel that there may be something positive to the challenges to clinical trials caused by COVID-19.

Lipset sees potential changes in telemedicine but says it is important to ensure that the right changes persist and outlast COVID-19.

Kasher wants to see the insertion of more virtual components into clinical trials, the reduction in patient protocol and the distribution of investigational drugs to pharmacies and homes.


  1. The COVID-19 pandemic has the potential to accelerate the adoption of telemedicine and virtual trials.
  2. The challenge is to ensure that the right changes will outlast the pandemic.
  3. The FDA will play a key role in the adoption of virtual trials and remote monitoring.

“If one good thing emerges from this pandemic, it will be the use of remote/centralized monitoring in all clinical trials. Regardless of the cause, in 2020 we cannot have monitoring of ongoing trials compromised for any reason,” says Jeff Kasher, president of Patients Can’t Wait.

Article source: https://www.clinicalleader.com/doc/covid-hastens-embrace-of-virtual-trials-0001

#ClinicalTrials, #VirtualTrials, #COVID-19, #Telemedicine, #FDA

P.S. Staying up-to-date with what’s new in Clinical Trials? Get the latest articles summarized and delivered free to your e-mail inbox. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria for EUROLogin2020


Read more
Nubilaria ACTide @ SCOPE Virtual 2021

SCOPE – Summit for Clinical Ops Executives

Read more
Nubilaria Christmas wishes 2020

Merry Christmas and Happy new Year

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems